Sysmex : Presentation( PDF format / 1.1MB )

Business Results

Fiscal Year Ended March 31, 2026

Sysmex Corporation

May 14, 2026

Our Approach under the New Management Structure

• This is the first earnings briefing under the new management structure

• The previous mid-term management plan fell short of initial targets, due to factors including structural market changes caused by healthcare cost containment policies in China and divergence between plans and results in certain new business areas. We have taken to heart both the external factors and results related to our own response measures.

• We will accelerate initiatives aimed at enhancing corporate value under the following three policies.

We will review the business portfolio based on disciplined hurdle rates and prioritize allocation of resources to businesses with high future profitability.

We will strengthen the diagnostics business through the introduction of new products that meet customer expectations and the creation of new value through DX, thereby improving profitability, capital efficiency, and cash generation capability.

In addition to continuing progressive dividends, we implement shareholder returns combined with share buybacks.

Index

1. Executive Summary

2. Business Results, Fiscal Year Ended March 31, 2026

3. Strategic Themes under the Mid-Term Management Plan

4. Financial Forecast for the Fiscal Year Ending March 31, 2027

(Appendix)

1. Executive Summary
   
   
   
   Executive Summary (Fiscal Year Ended March 31, 2026)

   Performance in the Americas, EMEA and AP remained solid, but net sales and profit declined due to the continued impact of healthcare cost containment policies in China and the recording of goodwill impairment losses.

Net sales

¥500.0 billion -1.7% YoY

Operating profit

¥51.8 billion -40.8% YoY

Profit attributable to owners of the parent

¥35.4 billion -33.9% YoY

Key reasons for lower sales and profits

• Continued impact of healthcare cost containment policies in China (principle of minimal necessity, distributor inventory adjustments, etc.)

  Sales in China down 24.9% (YoY, local currency basis)

• Total goodwill impairment losses at consolidated subsidiaries in new business areas of ¥11.2 billion

  Maintained the diagnostics business competitiveness

• Excluding China, sales (yen basis) +5.1% YoY

• Americas +7.3% / EMEA +5.2% / AP +6.4%

  (all on a local currency basis)

• Demand for hematology testing in China remained firm

  Forex impact

  • Net sales +¥10.2 billion ( - 3.7%)

  • SG&A expenses +¥4.63 billion (+5.9%)

  • Operating profit +¥0.09 billion (- 40.9%)

  Year-on-year change excluding foreign exchange effects is shown in parentheses.

Cash generation

Operating cash flow:

¥73.8 billion

Operating cash flow down 16% YoY

Free cash flow of ¥22.3 billion

Capital efficiency / profitability

ROE:

7.3%

ROIC: 7.6% / CCC: 205 days

Shareholder returns

Annual dividend:

¥38

Increase from previous year's ¥32: +18.8% Maintained progressive dividend policy (payout ratio: 67.3%)

Executive Summary (Forecast for Fiscal Year Ending March 31, 2027)

Net sales

¥535.0 billion +7.0% YoY

Operating profit

¥58.0 billion +11.9% YoY

Profit attributable to owners of the parent

¥36.0 billion +1.5% YoY

Assumptions for net sales (+7.0%)

• China (down 20%)

  －In addition to the principle of minimal necessity, assumptions include the impact of a standardization of testing prices.

• Americas +6% / EMEA +7% / AP +13% expected to remain strong (local

  currency basis)

• Japan Contribution from taking over JEOL's clinical chemistry business

  (clinical chemistry field：¥+10.0 billon）

  Assumptions for operating profit (+11.9%)

• Gross profit decline in China to be offset by growth in the diagnostics business and elimination of one-time factors (goodwill impairment losses)

• Assumes increases in raw material and logistics costs associated with U.S. reciprocal tariffs and worsening conditions in the Middle East

• Strengthen competitiveness of the diagnostics business (regional expansion + flagship product launches)

• Implement value chain reforms aimed at improving profitability

• Accelerate expansion in the hemostasis field and accelerate expansion in emerging markets

• Review the business portfolio

(Discussions initiated under the new management structure from April onward)

Cash generation Operating cash flow:

¥88.0 billion+19% YoY

Free cash flow of ¥27.0 billion (+21%)

Capital efficiency / profitability ROE:

7.3% ±0.0 pt YoY

ROIC 7.5% (-0.1 pt)

CCC 200 days (down five days)

Shareholder returns Annual dividend:

+5.3% from previous year's ¥38

Maintaining the progressive dividend policy

¥40

1. Business Results, Fiscal Year Ended March 31, 2026
   
   Financial Highlights (Year on Year)
   
   

   508.6 500.0

   Fiscal year ended

   March 31, 2026

   Fiscal year ended

   (Billions of yen)

   461.5

   410.5

   87.5

   363.7

   78.3

   73.6

   67.4

   51.8

   53.6

   44.0

   45.7

   49.6

   35.4

   
   
   

   YoY (Previous

   March 31, 2025

   (Billions of yen)

   period =

   Results Ratio Results Ratio

   100%)

   Net sales 500.0	100%	508.6	100%	98.3%
   Cost of sales 244.3	48.9%	236.6	46.5%	103.2%
   SG&A expenses 164.3	32.9%	150.8	29.7%	109.0%
   R&D expenses 29.1	5.8%	31.4	6.2%	92.7%
   Other income (10.3)	(2.1)%	(2.0)	(0.4)%	-
   Operating profit 51.8	10.4%	87.5	17.2%	59.2%
   Profit attributable to owners of the 35.4 parent	7.1%	53.6	10.6%	66.1%

   2022 2023 2024 2025 2026

   (Years to March 31)

   (expenses)

   Net sales
   
   Operating profit
   
   Profit attributable to owners of the parent
   
   

   	Fiscal year ended	Fiscal year ended
   	March 31, 2026	March 31, 2025
   1USD	¥150.8	¥152.6
   1EUR	¥174.8	¥163.8
   1CNY	¥21.2	¥21.1

   Breakdown of Net Sales (by Business and Field)

   Sales by Business and Field

Fiscal year ended March 31, 2026

YoY

(Previous period = 100%)

Hematology

(Billions of yen)

(Billions of yen)

Results Ratio Yen basis

Excluding FX impact

Excluding China

(Yen basis)

508.6

FCM

0.9

FX

impact

10.2 500.0

-8.4

2.6

Urinalysis

Others

LS

2.4 1.9

-12.6

Hemostasis -3.6

-2.0

Immunochemistry

Medical robotics

- ¥8.6 billion

FCM 4.6 0.9% 128.9% 125.0% 123.9%

Urinalysis 44.0 8.8% 107.9% 106.5% 117.5%

Hemostasis

72.4

14.5%

87.9%

84.6% 103.3%

Immunochemistry 22.3 4.5% 86.3% 86.1% 93.3%

Clinical chemistry 2.9 0.6% 80.3% 80.5% 88.7%

Life science 24.9 5.0% 117.1% 111.7% 117.1%

Others 25.9 5.2% 115.7% 111.8% 115.8%

2025

(Years to March 31)

2026

Medical robotics

3.3 0.7% 61.5% 61.4% 61.5%

Diagnostic business

496.7

99.3%

98.7%

96.7% 105.7%

business

Breakdown of Net Sales (by Destination and Product Type)

(Billions of yen)

Fiscal year ended March 31, 2026

YoY (Previous period = 100%)

Local currency

Major Reasons for Changes by Destination

Note: On a local currency basis

Results Ratio Yen basis

basis

Net sales 500.0 100.0% 98.3% 96.3%*

(Billions of yen)

6.6

508.6

3.2

10.2

500.0

-29.2

-9.1

By Destination

*Year -on-year change on a yen basis, excluding the impact of exchange rate fluctuations

9.6

By Product Type

508.6

(Billions of yen)

-3.9

10.2

500.0

-11.0

0.1

3.7

2025 Americas EMEA China AP Japan FX impact 2026

(Years to March 31)

2025 Instruments Reagents Services Others FX impact 2026

(Years to March 31) 11

Information by Destination (Americas)

ended March ended March

Sales (Million USD)

820.7 859.8

743.0 781.7

922.1

251.8

Services, others

• Instruments

  • Installations progressed steadily, and performance was favorable in the hematology and urinalysis fields.

  • In particular, in the urinalysis field, installations at large-scale facilities progressed in both North America and Central and Latin America.

• Reagents

  196.2

  204.3

  342.5

  205.6

  213.9

  362.2

  213.7

  214.7

  392.3

  236.4

  190.1

  433.2

  216.9

  453.4

  Instruments

  Reagents

  • Sales increased, supported by solid performance in the hematology and urinalysis fields.

  • In the hemostasis field, reagent sales are expected to increase going forward in line with growth in instrument placements.

  • Amyloid β testing reagents also remained firm (Net sales: USD 9.3 million, up 39.3% year on year).

2022 2023 2024 2025 2026

(Years to March 31) 12

Information by Destination (EMEA)

(Million EUR)

Fiscal year ended March

Fiscal year ended March

YoY

(Previous period = 100%)

31, 2026

31, 2025

Local currency basis

Yen basis

• Instruments

  
  
  

  • Through direct sales, performance in the hematology and urinalysis fields was favorable in Italy, while in France we achieved the winning of major tenders for

    Sales (Million EUR)

    798.7 857.9

    902.7

    Services, others

    the XR -Series at commercial labs.

  • In the hemostasis field, sales increased following the acquisition of large-scale tenders in Germany, France,

    722.8 746.2

    125.1

    132.0

    136.5

    and other countries.

    123.2

    187.2

    412.5

    121.0

    193.6

    431.6

    194.0

    479.6

    199.8

    526.0

    214.6

    551.5

    Instruments

    Reagents

    • Reagents

      • Sales increased across all fields, including strong performance in the urinalysis field driven by growth in the installed instrument base.

      • In the hemostasis field, sales also expanded in Germany, Egypt, and other countries in line with the

    2022 2023 2024 2025 2026

    (Years to March 31)

    Note: Sales figures, including for past fiscal years, exclude Russia.

    increase in the installed instrument base.

    13

    
    
    

    Information by Destination (China)

    (Million CNY)

    Fiscal year ended March 31, 2026

    Fiscal year ended March 31, 2025

    YoY

    Sales declined due to the expanding impact of healthcare cost containment policies (including the principle of minimal necessity), as well as continued inventory adjustments driven by deteriorating distributor finances.

(Previous period = 100%)

Local

currency basis

Sales (Million CNY)

5,437 5,605

Yen basis

• Instruments

  • Sales declined due to lower appetite for capital investment and distributor inventory adjustments, among other factors.

  • In the hemostasis field, sales increased, with steady performance continuing from the second half of the previous fiscal year, supported by the impact of

5,313

575

1,151

3,586

4,907

622

767

3,517

648

745

4,043

718

738

4,148

4,207

437 538

3,231

Services, others Instruments

Reagents

knockdown local production.

• Reagents

  • Due to the expanded impact of the principle of minimal necessity, the number of tests declined, particularly in the hemostasis field.

  • Sales in the hematology field also declined due to the impact of inventory adjustments associated with

    2022 2023 2024 2025 2026

    (Years to March 31)

    deteriorating distributor finances.

    14

    
    
    Outlook for China

    We expect negative growth to continue throughout the fiscal year ending March 31, 2027. We will continue to closely monitor developments while incorporating uncertainty associated with the standardization of testing prices.

    YoY Change in Net Sales (Conceptual)

    (pt)

    FY3/26 (Full Year):

    -25% (Local Currency Basis)

    FY3/27 (Full Year):

    -20% (Local Currency Basis)

    -4.9%

    -10.0%

    -24.9%

    -21.1%

    -28.0%

    FY3/26 Q1

    FY3/26 Q2

    FY3/26 Q3

    -38.5%

    FY3/26 Q4

    FY3/27 1H

    FY3/27 2H

    
    
    

    FY3/26 results: Q4 progressed generally as expected

    • Impact of the principle of minimal necessity and distributor inventory adjustments continued

    0

    Outlook for FY3/27

    • Our forecast newly incorporates the impact of the standardization of testing prices being advanced by the Chinese government.

    Note:

    We will monitor the situation closely and disclose important changes in a timely manner.

    Distributor inventory adjustments Principle of minimal necessity

    Other factors (VBP, competition, etc.) Impact of testing price standardization

    Future initiatives

    • Further strengthen the direct sales structure targeting Tier 3 hospitals in the hematology field

    • Expand the portfolio in the diagnostics business

Overall impact (%)

Organic growth + portfolio expansion, etc.

Demand for hematology testing in China remains firm, and the Company's brand value remains strong.

Over the medium to long term, we will rebuild competitiveness through higher added value and strengthening of the direct sales structure.

Changes in the Testing Market Environment in China

• Changes in the market structure

  To date

  Instruments were tools for generating profits

  Focus on testing throughput and durability

  Testing was a source of hospital revenue

  Shift toward a sustainable healthcare

  • Centralized procurement

    Going forward

    Testing instruments will become tools for improving productivity and patient satisfaction

    Shift toward solving issues and emphasizing added value

    Testing will become a cost center for hospitals

    • Increase in testing parameters and testing volume

    • Testing prices set by region and hospital

      • Principle of minimal necessity

      • Standardization of testing prices

  Negative impact

  • Increased cost pressure

    Positive impact

  • Increased demand for more sophisticated and complex testing workflows

  • Consolidation and outsourcing of testing operations, etc.

    → Expected increase in demand for system products

    
    
    

    Providing high-quality customer care

Prioritize achieving customer satisfaction through quality and service

Received top customer satisfaction ranking at the China Medical Industry Data Conference (March, 2026)

Strengthening direct sales

Deliver Sysmex strengths directly to customers

Information by Destination (AP)

Note: Figures in parentheses exclude the impact of exchange rate fluctuations.

Net Sales (Billion JPY)

Diagnostics business

Medical robotics business

• Total cumulative installations: four units.

• The number of surgeries continues to increase steadily, with more than 150 procedures performed in both Singapore and

2022＊

2023＊

2024 2025 2026

(Years to March 31)

Malaysia.

*Excludes sales in Russia

Includes sales in Russia 17

Information by Destination (Japan)

(Billions of yen)

Fiscal year ended March 31, 2026

Fiscal year ended March 31,

2025

YoY (Previous period = 100%)

Yen basis

Net sales 58.6 67.7 86.5%

Sales (Billion JPY)

67.7

Diagnostics business

• Instruments

  • Sales declined in reaction to the replacement demand for legacy products in the hematology field in the previous fiscal year.

  • In the urinalysis field, both instrument replacement demand and new installations remained favorable.

• Reagents

  • Sales declined due to the impact of sales brought forward in the

    55.6

    1.2

    59.8 62.1

    2.3 3.7

    4.8

    10.2

    58.6

    3.1

    Medical robotics business

    fourth quarter of the previous fiscal year associated with the transition to a new system.

    9.2

    9.5

    35.5

    9.7

    9.7

    38.0

    9.7

    12.0

    36.6

    13.6

    39.1

    11.0

    10.0

    34.4

    Services, others Instruments

    Reagents

    • Multiple new immunochemistry reagent parameters were launched.

      Medical robotics business

    • Installation results were below the previous fiscal year due to continued weak appetite for capital investment among hospitals.

      • Number of units installed during the fiscal year: 20 units (21 units globally)

        2022 2023 2024 2025 2026

        (Years to March 31)

      • Cumulative installed base: 106 units (110 units globally)

18

Breakdown of Operating Profit (Year on Year)

Lower R&D expenses 2.2

Change in other income and expenses

-8.8

FX

impact

0.09

Deterioration in the cost of sales ratio

-10.1 Higher

SG&A

expenses

-10.8

Fluctuation in gross profit due to changes in net sales

2025

- ¥35.7 billion

(Years to March 31)

-8.2

(Billions of yen)

2026

Note: Figures and comments below exclude the impact of exchange rates.

• Fluctuation in gross profit due to changes in net sales: - ¥10.10 billion

• Deterioration in the cost of sales ratio: - ¥10.89 billion

  (2.2pt deterioration)

  • Negative factors: Q1 inventory revaluations, 0.4pt

    Impact of product mix, 0.4 pt Deterioration of service costs, 0.6 pt Tariff impact, 0.4 pt

    Deterioration in logistics costs, 0.2 pt

• Higher SG&A expenses: - ¥8.87 billion

  • Labor costs rose ¥2.5 billion, due to personnel increases owing to expansion of the direct sales area, as well as higher unit costs.

  • Other costs rose ¥1.3 billion in line with an increase in scale and sales promotion activities.

  • Depreciation and amortization rose ¥2.95 billion owing to the launch of core systems operations

• Lower R&D expenses: + ¥2.29 billion

  • While investment in product development continues, total R&D expenses declined due to prioritization and narrowing of research themes.

• Change in other income and expenses: - ¥8.27 billion

  • Goodwill impairment losses: - ¥11.2 billion

• FX impact: +¥0.09 billion

  
  
  Goodwill Impairment Losses at Consolidated Subsidiaries

  Based on the review of business plans under the new management structure,

  we redesigned resource allocation with a greater focus on profitability and capital efficiency.

• We reevaluated the business plans of each consolidated subsidiary in line with the policies of the mid-term management plan and the capital allocation discipline under the new management structure.

• For goodwill recognized at the time of acquisition, full impairment losses were recorded based on future cash flow outlooks, changes in the business environment, and strategic revisions.

• Development and manufacturing in the FCM field

Impairment loss: ¥1.5 billion

Total: ¥11.2 billion

• Going forward, we will apply financial discipline metrics such as ROIC, IRR, and payback period as hurdle rates tailored to business characteristics, and promote disciplined resource allocation in line with the policy of "selection and concentration"

Breakdown of Changes in the Consolidated Statement of Financial Position

Assets Liabilities/Equity

Current assets: +¥23.78 billion Non-current assets: +¥18.47 billion

Property, plant and

(Billions of yen)

Other non-current

Intangible assets

Liabilities: +¥1.12 billion Equity: +¥41.14 billion

(Billions of yen)

Other equity

20.18

1.02

707.5

Cash and cash equivalents

665.2 5.77

-5.45

Inventory 9.66

13.80

Other current assets

-10.06

Goodwill

Trade and other receivables

+¥42.26 billion

equipment

assets

7.33

Retained

27.71

707.5

Non-current liabilities

4.68

earnings

13.43

665.2

Current liabilities

-3.56

+¥42.26 billion

2025

(Years to March 31)

2026

2025

(Years to March 31)

2026

Cash Flows

(Billions of yen)

88.2

(Billions of yen)

(Billions of yen)

(Billions of yen)

63.9

73.8

differences on cash and cash equivalents

6.0

14.0

-9.0

-5.4

-24.3

-37.6

* Includes translation

-54.9

-52.4

-51.4

2024 2025 2026

(Years to March 31)

Proposed Dividend for the Fiscal Year Ended March 31, 2026

*We plan to propose this year-end dividend to the 59th Ordinary General Meeting of Shareholders.

1. Strategic Themes under the Mid-Term Management Plan

Accelerated Rollouts in the Hemostasis Field

Expansion of sales in EMEA and the Americas due to a global OEM agreement

*Growth rate forecast for the fiscal year ending March 31, 2027 compared with the fiscal year ended March 31, 2026 (local currency basis)

EMEA

+20% or more*

Americas

+70% or more*

Current: Won numerous large tenders, including from laboratory chains in Germany and projects in France and Switzerland

Outlook: Reagent sales expected to grow in line with the increase in installed instrument base

Current: Obtained FDA approval for the full reagent lineup, including specialty parameters, establishing a framework capable of meeting a broad range of testing needs

Outlook: Sales growth to accelerate through expanded adoption in high-end markets, centered on the CNTM-9000, which launched in the previous fiscal year

Key countries with major new tender wins

CN-Series automated blood coagulation analyzer

Hemostasis-related reagents

CN-9000 automated hemostasis solution

Business Expansion in Emerging Markets

• Net Sales (Full Year)

Emerging markets

(Asia, Central and South America, the Middle East and Africa)

Key initiatives in the fiscal year ending March 31, 2027

• India: Leveraging competitive advantages

12.4

14.5

36.3

(Billions of yen)

54.3

Asia Central and South America the Middle East and Africa

63.5 74.1

22

86.5

• Expansion of Make in India Class I products

  
  
  

  XQ -320 multiparameter automated

• Preparation for the launch of strategic

18.8 22.2

15.8

models and public health services

hematology analyzer for the Indian market New functionality: Improved anemia classification performance (RUO)

India

(Million INR)

2024 2025 2026 2027 (Forecast)

(Years to March 31)

+15.4%

2024 2025 2026 2027 (Forecast)

(Years to March 31)

• Brazil: Commencement of construction of a new plant and acceleration of growth in the urinalysis and hemostasis fields

  7,239

At full operation, production capacity is

Brazil

(Million USD)

+19.4%

expected to be

approximately doubled

(compared with the current Brazil plant)

Artist's rendering of the new plant in Brazil, which is scheduled for completion in the fiscal year ending March 31, 2028

Strengthening the Competitiveness of the Diagnostics Business

XR-1000

(North America)

North America: Transition from the

XNTM-Seriies to an XR-Series Launch Achieve an overwhelming No. 1 global market position

India: Launch of Make in India products

・Strengthen competitive advantage

Launch of next-generation flagship models

・Moving to a new stage beyond screening

Following Europe, rollout of a full lineup including specialty parameters in North America

Launch of next-generation flagship models(Japan)

CN-Series (North America)

Start of reagent sales growth in Europe

Global expansion

・Achieve a market share of over 10% for Sysmex alone in Europe and the Americas

HISCLTM-5000

Mid-Scale change (Japan)

Three reagent parameters, including procalcitonin (Japan)

Aβ42/40: Launch in the U.S. as an LDT

Launch of compact models

Evaluation toward introduction of LDT panel testing parameters

(p-Tau217/p-tau205/MTBR-Tau)

Launch of next-generation flagship models(Japan)

Global expansion

Succession and Future Expansion in the Clinical Chemistry Field

BioMajesty JCA-ZS050

Took over JEOL's clinical chemistry business in April

• Obtained a top domestic market share in clinical chemistry analyzers

• Acquired technologies for reagent miniaturization and high-throughput processing of tests

  2. Global expansion leveraging the sales network

Extensive sales network covering 190 countries and regions worldwide

Improve the low-profitability model centered on standalone analyzers

Fiscal year ending March 31, 2027

Transition to the reagent business (Japan + overseas))

Fiscal year ending March 31, 2028

Reagent business

full-scale global expansion

Fiscal year ending March 31, 2029

Initiatives to Improve Profitability

• Improve the product mix

• Boost reagent profitability

• Optimize the supply chain

• Optimize production and inventory by improving the accuracy of demand forecasting

• Improve operational efficiency and effectiveness through digitalization

  • Curtail hiring of new staff

  • Speed up transition from development to mass production

Improvement of profitability and efficiency

Started discussions and evaluations under the new management structure

Enhance Profitability through Reforms to the Value Chain

Improve profitability by expanding the reagent business and reducing costs

Improve the product mix

• Increase the proportion of high-profitability products, including reagents in the hemostasis field in Europe and the Americas

• Raise average selling prices in line with new product launches

Improving the Gross Profit Margin (Conceptual Image)

Optimize the supply chain

• Reduce costs by optimizing reagent production sites and supply frameworks

FY03/2026

FY03/2027 FY03/2028 FY03/2029

Review the Business Portfolio

We will provide disclosures and updates on important matters as appropriate in a timely manner.

4. Financial Forecast for the Fiscal Year Ending March 31, 2027



Financial Forecast for the Fiscal Year Ending March 31, 2027

Capital expenditure:

¥48.0 billion

Depreciation and amortization: ¥47.0 billion

(Billions of yen)

508.6

500.0

87.5

51.8

53.6

35.4

36.0

58.0

535.0

• Assumed Exchange Rates

  Previous

• Exchange Rate Sensitivity

2025 2026 2027

Full-year assumptions

results

(Fiscal year ended March 31, 2026)

Net sales (year)

Operating profit (year)

(Years to March 31)

Net sales

Operating profit



Breakdown of Net Sales and Operating Profit for the Fiscal Year Ending March 31, 2027

Net Sales Operating Profit

Growth in the clinical chemistry

business FX

(Billions of yen)

Higher gross

13.7

Impact of U.S.

reciprocal tariffs

Increases in SG&A and

(Billions of yen)

Diagnostics business

28.2 2.2

Medical robotics business

9.9

-17.2

Lower sales in China

impact

+¥35.0 billion

11.9

535.0

profit on increased sales

20.3

-1.0

Elimination of temporary factors

-6.7

R&D expenses

Impact of lower sales in China

500.0

51.8

Deterioration

in the cost of sales ratio

-14.5

-9.1

3.5

FX

impact

58.0

+¥6.2 billion

2026

(Years to March 31)

2027

2026

(Years to March 31)

2027

(Forecast) (Forecast)

Capital Allocation (Outlook for the Fiscal Year Ending March 31, 2027)

Operating cash flow*

Generate cash through earning power

*Before R&D tax credits

Active use of borrowings and other financing

Review the Business Portfolio, etc.

Shareholder returns

Maintain a 40% dividend payout ratio and a progressive dividend policy + share buybacks (up to ¥30.0 billion)

Strategic investments (Including consideration paid for the takeover of JEOL's business)

Business operations and R&D

R&D expenses

(Including internally generated intangible assets)

Capital investment

(facility development and expansion of the leasing business) Net sales ratio: Approx. 9%

(including medical DX)

Diagnostics business Medical robotics business New technologies and businesses

Prioritize allocation to the diagnostics business

Dividend Forecast for the Fiscal Year Ending March 31, 2027

In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 40% , adopt progressive dividend approach under our basic policy of sharing the successes of our operations in line with

business performance.

(Yen)

Dividend (annual) based on a conversion to shares following the stock split on April 1, 2024

38

Payout ratio (consolidated)

32

23.33

24

24

25.33 27.33

28

67.4%

67.3%

17.33 19.33

22

12.67

29.6%

43.1% 47.1%

36.0% 37.5% 35.4% 37.4%

18.9%

22.6%

17.8% 17.9%

26.8%

20.0%

31.9%

29.4%

27.0%

29.1% 29.1%

9

27.1%

27.5% 29.7%

35.1% 35.4%

4.17

4.67

5

5.67

6.67

1.04

1.25

1.67

2.17

3

4

40

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

Proposed Forecast

Up to ¥30.0 billion share buyback

Note: The payout ratio for the fiscal year ending March 31, 2027 is calculated based on the Company's forecasts, including an assumed share buyback.

(Appendix)



Quarterly Results for the Fiscal Year Ended March 31, 2026

Financial Forecast for the Fiscal Year Ending March 31, 2027 (Sales by Business, Field, and Destination)

Sales by business and field Sales by destination

Highlights (April 2025 to April 2026)

• Sysmex's CN-6000 Automated Blood Coagulation Analyzer and XR-Series Automated Hematology Analyzer Receive U.S. FDA 510(k) Clearance

• Sysmex Establishes a Subsidiary in Kenya and Greece (EMEA)

• Sysmex Group's New Manufacturing Base in India Begins Full-Scale Operations and Launches "Make in India" Products (AP)

• Sysmex Expands Portfolio and Accelerates Global Expansion through Acquisition of JEOL's Clinical Chemistry Testing Business

• Introduction of Compact Model to the CN-Series: Launch of the CN-700 Automated Blood Coagulation Analyzer (Japan)

• Sysmex Launches an Assay Kit for Identifying p-Tau217 in the Blood, a Biomarker Related to Alzheimer's Disease

  Sustainability

• Sysmex Introduces Performance-Linked Stock Compensation Plan

• Sysmex Becomes First in the Industry to Obtain Certification for Closed-loop Recycling of Reagent Containers under the Plastic Resource Circulation Act

• Balancing Business Growth and Reducing Environmental Impact as the Industry's First TNFD Adopter

• Sysmex Selected for DDP 2025 "Climate Change" A List

• Sysmex Ranked in the Top 1% in the Sustainability Yearbook 2026 by S&P Global